NPPA releases revised MRPs for 543 brands of anti-cancer medicines, effective 9 November 2026
On 28 October 2026, the National Pharmaceutical Pricing Authority released revised Maximum Retail Prices for 543 brands of anti-cancer medicines, effective from 9 November 2026.
Summary
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, released a list of 543 brands of anti-cancer medicines with revised Maximum Retail Prices (MRPs) on 28 October 2026. The new prices take effect from 9 November 2026, and the list will be updated as manufacturers submit revised prices. The revision follows NPPA's Trade Margin Rationalisation of 137 non-scheduled anti-cancer drugs announced on 17 October 2026 to curb excessive trade margins. These drugs include immunotherapy medicines, Denosumab, Pegfilgrastim and Bevacizumab.
Key facts
- Authority
- National Pharmaceutical Pricing Authority (NPPA)
- Under
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
- Brands with revised MRP
- 543 anti-cancer brands
- Effective
- 9 November 2026
- Basis
- Trade Margin Rationalisation (TMR) announced 17 October 2026
- Drugs covered by TMR
- 137 non-scheduled anti-cancer drugs
- Examples
- Immunotherapy drugs, Denosumab, Pegfilgrastim, Bevacizumab
Practice MCQs 2 questions
In October 2026, NPPA released revised MRPs for how many brands of anti-cancer medicines?
Show answer
Correct answer: B — 543
The National Pharmaceutical Pricing Authority (NPPA) functions under which department?
Show answer
Correct answer: C — Department of Pharmaceuticals